Omacetaxine Mepesuccinate · Synribo, CGX-635

What is Omacetaxine Mepesuccinate?

Omacetaxine mepesuccinate is a semisynthetic plant alkaloid that binds the ribosome and inhibits protein synthesis, reducing levels of oncoproteins including Bcr-Abl and anti-apoptotic proteins.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Synribo, CGX-635, NSC-141633, homoharringtonine

Drug type

Small molecule

Targets

80S ribosome, Bcr-Abl (BCR) (secondary target)

Mechanism

Inhibitor of 80S ribosome

Pathways

protein synthesis inhibition, apoptosis

Therapy area

Hematology, Oncology

Developer

Teva Pharms Intl (TEVA)

Also in trials of

AAPG

FDA status

Approved as Synribo (October 26, 2012), NDA203585 · FDA label

UNII

6FG8041S5B

✅ FDA-approved uses

• Chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors

From the indications section of the FDA label (version of Sep 30, 2022). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Myeloid MalignancyRelapsed/Refractory Acute Myeloid LeukaemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myelomonocytic Leukemia (M4)

More from Teva Pharms Intl

Sources

• FDA label (DailyMed)
• FDA label Synribo (2022-09-30), indications
• NCI Thesaurus
• NCI Thesaurus
• ClinicalTrials.gov NCT02835794
• ClinicalTrials.gov NCT04126681
• ClinicalTrials.gov NCT04501120
• ClinicalTrials.gov NCT04501120

Updated Oct 3, 2026. Something wrong or missing? Report it on the TEVA page.